United Therapeutics (NASDAQ:UTHR) Price Target Raised to $600.00

United Therapeutics (NASDAQ:UTHR) had its price target upped by Oppenheimer from $575.00 to $600.00 in a research note published on Thursday morning, Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also recently issued reports on the company. Bank of America decreased their target price on United Therapeutics from $303.00 to $280.00 and set an “underperform” rating on the stock in a report on Thursday, August 1st. LADENBURG THALM/SH SH cut United Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 1st. Morgan Stanley downgraded United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $310.00 to $321.00 in a report on Thursday, July 11th. TD Cowen lifted their price target on United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. Finally, Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday. One analyst has rated the stock with a sell rating, two have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Stock Performance

UTHR opened at $374.02 on Thursday. United Therapeutics has a one year low of $208.62 and a one year high of $377.92. The stock’s fifty day moving average is $355.40 and its 200-day moving average is $316.65. The company has a market capitalization of $16.70 billion, a PE ratio of 16.43, a P/E/G ratio of 1.35 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.16 by $0.23. The business had revenue of $748.90 million for the quarter, compared to analysts’ expectations of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company’s quarterly revenue was up 22.9% on a year-over-year basis. During the same period in the previous year, the firm posted $5.38 EPS. On average, equities research analysts forecast that United Therapeutics will post 24.85 EPS for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $833,350.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other United Therapeutics news, COO Michael Benkowitz sold 25,000 shares of the business’s stock in a transaction dated Wednesday, August 7th. The stock was sold at an average price of $323.38, for a total value of $8,084,500.00. Following the completion of the sale, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $833,350.26. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO James Edgemond sold 7,782 shares of the business’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $366.99, for a total value of $2,855,916.18. Following the completion of the sale, the chief financial officer now directly owns 6,426 shares of the company’s stock, valued at $2,358,277.74. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,412 shares of company stock worth $33,971,508 over the last 90 days. 11.90% of the stock is currently owned by corporate insiders.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in UTHR. LSV Asset Management lifted its position in shares of United Therapeutics by 82.5% in the second quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after buying an additional 436,851 shares during the last quarter. Swedbank AB acquired a new stake in shares of United Therapeutics in the first quarter worth about $97,316,000. Nordea Investment Management AB lifted its position in shares of United Therapeutics by 677.6% during the 1st quarter. Nordea Investment Management AB now owns 300,920 shares of the biotechnology company’s stock worth $72,422,000 after purchasing an additional 262,222 shares during the last quarter. Canada Pension Plan Investment Board lifted its position in shares of United Therapeutics by 567.2% during the 1st quarter. Canada Pension Plan Investment Board now owns 180,800 shares of the biotechnology company’s stock worth $41,533,000 after purchasing an additional 153,700 shares during the last quarter. Finally, Assetmark Inc. lifted its position in shares of United Therapeutics by 56.9% during the 3rd quarter. Assetmark Inc. now owns 419,957 shares of the biotechnology company’s stock worth $150,492,000 after purchasing an additional 152,249 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.